Journal Club:Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE)-Recording

Video Transcription

Video Summary

In the IGCS Education 360 Journal Club, Dr. Cathy Han and Dr. Kevin Albuquerque discussed the results of the Interlace Trial, exploring induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone in treating locally advanced cervical cancer. The study, presented by Dr. Mary McCormick and Dr. Gemma Amikowicz, showed that induction chemotherapy (weekly carboplatin and paclitaxel) significantly improved both progression-free and overall survival rates. The trial highlighted an unmet need in cervical cancer treatment, indicating potential benefits even with advanced imaging and treatment techniques. Key takeaways included practical tips for treatment application, such as planning radiation simulations early in the chemotherapy phase and ensuring multidisciplinary collaboration for efficiency. There was notable discussion around the adherence to regimens and treatment scheduling, emphasizing the importance of not using induction chemotherapy to manage radiotherapy waiting lists. While the trial did not include patients with periortic nodal involvement, it was stressed that judicious selection of patients for induction chemotherapy should always consider logistics and resources, especially in lower-income settings. The potential integration of immunotherapy with this regimen remains an exciting future research avenue.

Keywords

Interlace Trial

induction chemotherapy

chemoradiotherapy

cervical cancer

progression-free survival

overall survival

multidisciplinary collaboration

immunotherapy